Studies show that opioids are the number one prescribed medication for peripheral neuropathy contrary to evidence suggesting a lack of efficacy. Despite being a common condition for individuals with diabetes, treatment is often non-evidence based, meaning that creating a care plan can be difficult. With this, the American Academy of Neuropathy (AAN) was urged to re-evaluate treatment recommendations for Diabetic Neuropathy Pain (DNP). Listen in as Dr. John Swegle, a pain management expert, and host Geoff Wall discuss the updates on DNP treatment recommendations.
00:00 – Introductions
02:05 – The American Academy of Neuropathy Guideline Update
05:29 – Treating and Controlling Diabetes
06:27 – Comparing Gabapentinoids, Sodium Channel Blockers, SNRIs, Opioids, and TCAs
12:30 – The GameChanger
19:29 – The American Academy of Neuropathy Recommendations
24:49 – Closing Remarks
John Swegle, PharmD, BCPS, BCACP Clinical Associate Professor University of Iowa College of Pharmacy
John received his PharmD degree from the University of Iowa. He currently is a Clinical Associate Professor with the University of Iowa and clinical pharmacist with the Mercy Family Medicine Residency Program. In addition, he works with Hospice of North Iowa serving as a consultant pharmacist and as a faculty member for the Mercy Medical Center – North Iowa Palliative Medicine Fellowship.
Links to Resources:
How to Claim CE
CE is available for CEimpact members.
Need a membership?
1. Select an appropriate first line medication for diabetic neuropathic pain (DNP) based on the 2022 guidelines
2. Describe the treatment effects of the drugs used for DNP in the 2022 guidelines
Dr. Wall is a member of the Janssen Speaker's Bureau.
Dr. John Swegle reports no actual or potential conflicts of interest associated with this episode.
Continuing Education Information:
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-057-H01-P
Initial release date: 01/03/22
Expiration date: 01/03/2023
Additional CPE & CME details can be found here.